BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 7547095)

  • 1. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE; Mesure R
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
    Rosenfeld WE; Doose DR; Walker SA; Nayak RK
    Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel.
    Song S; Chen JK; Yang PJ; He ML; Li LM; Fan BC; Rekers H; Fotherby K
    Contraception; 1992 Jun; 45(6):523-32. PubMed ID: 1535580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
    Kuhnz W; al-Yacoub G; Fuhrmeister A
    Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control, and safety of a new low dose oral contraceptive containing 20 micrograms ethinyl estradiol and 100 micrograms levonorgestrel over six treatment cycles.
    Bannemerschult R; Hanker JP; Wünsch C; Fox P; Albring M; Brill K
    Contraception; 1997 Nov; 56(5):285-90. PubMed ID: 9437556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of gestodene and desogestrel as components of low-dose oral contraceptives on the pharmacokinetics of ethinyl estradiol (EE2), on serum CBG and on urinary cortisol and 6 beta-hydroxycortisol.
    Hammerstein J; Daume E; Simon A; Winkler UH; Schindler AE; Back DJ; Ward S; Neiss A
    Contraception; 1993 Mar; 47(3):263-81. PubMed ID: 8462317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
    Carlborg L
    Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a triphasic oral contraceptive containing desogestrel and ethinyl estradiol.
    Archer DF; Timmer CJ; Lammers P
    Fertil Steril; 1994 Apr; 61(4):645-51. PubMed ID: 8150105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives.
    Sinofsky FE; Pasquale SA
    Am J Obstet Gynecol; 1998 Feb; 178(2):300-4. PubMed ID: 9500490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
    Young A; Anzures-Cabrera J; Derks M
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
    Cawello W; Rosenkranz B; Schmid B; Wierich W
    Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.
    Ouellet D; Hsu A; Qian J; Locke CS; Eason CJ; Cavanaugh JH; Leonard JM; Granneman GR
    Br J Clin Pharmacol; 1998 Aug; 46(2):111-6. PubMed ID: 9723818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole does not affect the bioavailability of oral contraceptives.
    Fuchs W; Sennewald R; Klotz U
    Br J Clin Pharmacol; 1994 Oct; 38(4):376-80. PubMed ID: 7833230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cyproterone acetate and ethinylestradiol in 15 women who received a combination oral contraceptive during three treatment cycles.
    Kuhnz W; Staks T; Jütting G
    Contraception; 1993 Dec; 48(6):557-75. PubMed ID: 8131397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
    Endrikat J; Müller U; Düsterberg B
    Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study.
    Johnson-Agbakwu C; Brown L; Yuan J; Kissling R; Greenblatt DJ
    Clin Ther; 2018 Jan; 40(1):64-73. PubMed ID: 29198449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.